EVE Evolva Holding SA

Neil Goldsmith Stepping Down as CEO and Board Member of Evolva

Evolva (SIX: EVE) today announces the departure of CEO Neil Goldsmith and his succession by the current Chief Operating Officer (COO), Simon Waddington.

Since co-founding Evolva, Neil Goldsmith has been instrumental in Evolva’s development over the last thirteen years, moving the company from a pharmaceutical oriented biotech start-up to a listed business developing and selling specialty ingredients for health, wellness and nutrition markets. Neil’s entrepreneurial approach has led to the launch by Evolva of products such as nootkatone and resveratrol, and the advancement of best-tasting stevia products to an anticipated launch in 2018, as communicated earlier this year.

Evolva’s Board and executive management have recently determined that the near-term focus needs to be on growing the market opportunity for Evolva’s products and delivering attractive margins. This more focused approach is not a natural fit with Neil’s entrepreneurial strengths, something recognized by both Neil and the Board. As a consequence Neil and the Board have mutually agreed that Neil will step down as CEO and member of the Evolva Board with immediate effect.

Neil will be succeeded by Simon Waddington, currently COO of Evolva. Simon had previously been the CEO of Abunda Inc. until its acquisition by Evolva in 2011 upon which he joined the management team. His background and experience is ideally suited to the next phase of Evolva’s evolution.

Gerard Hoetmer, Chairman of Evolva’s Board of Directors, said “On behalf of the whole Board, I would like to thank Neil for all his efforts to bring Evolva to where it is today. We are confident that under Simon’s leadership the next steps in the transformation of Evolva to a product-based business can be made. More information on the transformation will be shared at the half-year results announcement on August 14th.”

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

EN
06/07/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evolva Holding SA

 PRESS RELEASE

Shareholders of Evolva Holding SA in liquidation approve BoD proposals...

Evolva Holding SA / Key word(s): AGMEGM Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected 12.04.2024 / 19:10 CET/CEST PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR   Shareholders of Evolva Holding SA in liquidation approve proposals put forward by the Board of Directors at Annual General Meeting; of the three agenda items put forward by Nice & Green, revocation of the liquidation and the delisting were also approved whereas introduc...

 PRESS RELEASE

Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG...

Evolva Holding SA / Key word(s): Takeover Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 28.12.2023 / 17:45 CET/CEST PRESS RELEASE   Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 Reinach, Switzerland, 28 December 2023 — Following the approval on 21 December 2023 by the shareholders of Evolva Holding AG (SIX: EVE) of the sale of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., the parties have successfully closed the transaction on 28 December 2023. Evolva Holding S...

 PRESS RELEASE

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss sub...

Evolva Holding SA / Key word(s): AGMEGM Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting 21.12.2023 / 17:45 CET/CEST PRESS RELEASE   Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting Reinach, 21 December 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved all the proposals put forward by the Board of Directors at today’s extraordinary general meeting (EGM). The sharehol...

 PRESS RELEASE

Evolva and Breko broaden partnership by signing agreement for the excl...

Evolva Holding SA / Key word(s): Agreement Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam 14.11.2023 / 07:00 CET/CEST PRESS RELEASE   Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTMResveratrol in Germany, Austria, Thailand and Vietnam Reinach, 14 November 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and Breko GmbH, Bremen, Germany (“Breko”), a leading supplier of p...

 PRESS RELEASE

Evolva shareholders approve increase of the conditional capital and up...

Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 24.08.2023 / 20:00 CET/CEST PRESS RELEASE   Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 Reinach, 24 August 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved the proposals put forward by the Board of Direct...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch